Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Protocol Number:
J13151
Phase:
Phase III
Physician:
Robin Avery
Purpose:
The primary objective of this study are to compare the safety and efficacy of CMX001 to placebo for the prevention of clinically significant CMV infection in R+ allogeneic hematopoietic stem cell transplant (HSCT) recipients. This is a randomized, doubleblind, placebo-controlled, parallel group, multicenter study of CMX001 in CMV-seropositive subjects who have undergone allogeneic HSCT. The study will comprise a screening evaluation, a treatment phase of 10 to 14 weeks� duration (through Week 14), followed by a 10-week posttreatment phase (to Week 24).
Eligibility:
Treatment:
The primary objective of this study are to compare the safety and efficacy of CMX001 to placebo for the prevention of clinically significant CMV infection in R+ allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Population:
Adult
Last Update
09/19/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer